3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
5
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Breast Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Brain Neoplasms
1
Interventions
antineoplaston AS 2-1
4
antineoplaston A10
4
Cyclophosphamide
4
Cisplatin
4
Temozolomide
3
Radiotherapy
3
dactolisib
2
Vincristine
2
Filgrastim
2
Everolimus
2
Etoposide
2
Bevacizumab
2
spartalizumab
1
sargramostim
1
pasireotide
1
ganitumab
1
gallium Ga 68 dotatate
1
fosbretabulin
1
cixutumumab
1
belzutifan
1
aldesleukin
1
Topotecan
1
Thiotepa
1
TH 302
1
Sunitinib
1
Standard of Care
1
Pregabalin
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroectodermal Tumors, Primitive
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts